Idera Pharmaceuticals Inc (NASDAQ:IDRA)

3.52
Delayed Data
As of Apr 01
 -0.19 / -5.12%
Today’s Change
1.94
Today|||52-Week Range
5.48
-20.18%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$437.2M

Company Description

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors. The company has two drug candidates, IMO-3100, a TLR7 and TLR9 antagonist, and IMO-8400, a TLR7, TLR8, and TLR9 antagonist, in clinical development for the treatment of autoimmune and inflammatory diseases. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.

Contact Information

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge Massachusetts 02139
P:(617) 679-5500
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Vincent J. MilanoPresident, Chief Executive Officer & Director
Louis J. ArcudiCFO, Secretary, Treasurer & SVP-Operations
Sudhir A. AgrawalDirector & President-Research
Louis BrennerChief Medical Officer & Senior Vice President
John Peter WolfSenior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account